EATRIS Transmed Academy training platform has a new look

Published 22 January 2024

The EATRIS Transmed e-learning platform  has been upgraded to Moodle 4.1. The online platform is for translational scientists and offers a range of self-paced online courses. It provides biomedical researchers at any career stage with a better understanding of translational research and medicines development.

The EATRIS Transmed e-learning platform has strongly benefited from a Moodle upgrade. The upgrade has user experience at its heart and features improved menu layouts for easier navigation and a contemporary design. The platform is aimed at translational scientists and offers a variety of online courses that users can follow at their convenience. The courses are free of charge and cover topics such as Introduction to Translational Medicine, Cell & Gene Therapy (ATMP) Development, Regulatory aspects of vaccine development, and Personalised Medicines.

The Transmed Academy e-learning platform is set in a tailored Moodle environment to provide a targeted learning experience and to make the best use of the multidisciplinary content. To keep track of each individual participant’s course progress and provide valuable feedback, we have implemented a user system, which is free of charge. Before you create a user, feel free to browse the course catalogue here.

 Explore the new platform directly here.

Examples of courses:

In this online self-paced course, you will be introduced to the concept of translational science and medicine, including:​ 

  • Introduction to Translational Medicine 
  • Target validation​ 
  • Predictive models​ 
  • Biomarkers​ 
  • Clinical Trial and Implementation​ 
  • Regulatory environment and Intellectual Property 

Target audience: anyone interested in learning more about translational medicine 

Investment time: This course has an average study load of 8 – 10 hours 

This online self-paced course  consists of 4 units representing the key challenges of the ATMPs development cycle – Scientific, Manufacturing, Reimbursement and Regulatory. Participants will have a chance to listen to talks by 12 top scientists, industry experts and regulators in the field, get acquainted with the relevant literature, and complete assignments such as developing a potency assay strategy for a new ATMP​, building a submission dossier for regulatory review for a new cell therapy​, and performing a Health Technology Assessment on an ATMP using the HTA Core Model.  

Target audience: anyone interested in the ATMPs development topic 

Investment time:  The course has ca. 10 hours of interactive lectures and nearly 30 hours of independent assignments and bonus materials 

View the course syllabus here.

In this online self-paced course, you will be introduced to regulatory aspects of vaccine development, including:​ 

  • How to navigate the regulatory maze 
  • Chemistry, Manufacture and Control (CMC) 
  • Regulatory landscape for preclinical testing 
  • Clinical Vaccine Development 
  • Cancer vaccines and ATMPs 
  • Scientific basis of Cancer vaccines 
  • COVID-19 vaccines development 

Target audience: professionals working on vaccine development who need an introduction to the (EU) regulatory requirements associated with the field 

Investment time: This course has an average study load of 8 – 10 hours 

View the course syllabus here. 

This course provides a brief overview of the personalised medicine research pipeline. It gives a quick explanation of the methodology that was followed to develop the recommendations, and presents each of the stages of the personalised medicine pipeline, their challenges and how the recommendations can help to strengthen the quality of the research.

Many of the courses featured on the Transmed Academy have been developed throughout European projects such as PERMIT and ADVANCE just to name a few. These projects have many partnering organisations who each bring their unique perspectives to the materials. This makes it a valuable resource to the EATRIS community and for advancing Translational Medicine.